A5047384681- Smoking Behavior and Cessation
- Behavioral Health and Interventions
- Substance Abuse Treatment and Outcomes
- Nicotinic Acetylcholine Receptors Study
- Obesity, Physical Activity, Diet
- Schizophrenia research and treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Policy Implementation Science
- Opioid Use Disorder Treatment
- Health, psychology, and well-being
- Cannabis and Cannabinoid Research
- Health disparities and outcomes
- Bipolar Disorder and Treatment
- School Health and Nursing Education
- Mental Health and Patient Involvement
- LGBTQ Health, Identity, and Policy
- Health and Wellbeing Research
- Mental Health Research Topics
- Quinazolinone synthesis and applications
- Eating Disorders and Behaviors
- Probiotics and Fermented Foods
- Synthesis and Characterization of Heterocyclic Compounds
- Mathematics Education and Teaching Techniques
- Pain Management and Opioid Use
- Child and Adolescent Psychosocial and Emotional Development
Johnson University
2015-2025
Rutgers, The State University of New Jersey
2015-2025
Rutgers Sexual and Reproductive Health and Rights
2015-2022
Rutgers Cancer Institute of New Jersey
2014-2019
Jackson Memorial Hospital
2019
University of Miami
2019
University of Newcastle Australia
2016
University of Oxford
2000-2015
World Health Organization - Pakistan
2013-2015
James Hutton Institute
2015
The National Institute of Mental Health (NIMH) convened a meeting in September 2005 to review tobacco use and dependence smoking cessation among those with mental disorders, especially individuals anxiety depression, or schizophrenia. Smoking rates are exceptionally high these contribute the medical morbidity mortality individuals. Numerous biological, psychological, social factors may explain rates, including lack treatment health settings. Historically, "self-medication" "individual...
Article AbstractObjective: Effective smoking cessation treatments are needed for patients with schizophrenia, who, compared the general population, have high rates of cigarette and more difficulty quitting. We evaluated safety efficacy varenicline in outpatients stable schizophrenia or schizoaffective disorder. Method: In this 12-week, randomized, double-blind, multicenter trial (May 8, 2008, to April 1, 2010), 127 smokers (≥ 15 cigarettes/d) DSM-IV-confirmed disorder received placebo (2:1...
Lower rates of smoking cessation and higher lung cancer in African American (AA) smokers may be linked to their preference for mentholated cigarettes.This study assessed the relationship between menthol smoking, race/ethnicity among a diverse cohort 1688 patients attending specialist service.46% smoked cigarettes, but significantly more AA (81%) Latino (66%) than Whites (32%) menthols. fewer cigarettes per day (CPD) non-menthol (15.7 vs. 20.3, AA, 17.0 22.1, Latinos), with no differences...
Smokers with co-occurring mental illness or substance use disorders are not designated a disparity group priority population by most national public health and tobacco control groups. These smokers fulfill the criteria commonly used to identify groups that merit special attention: targeted marketing industry, high smoking prevalence rates, heavy economic burdens from tobacco, limited access treatment, longer durations of less cessation. A effort increase surveillance, research, treatment is...
The capability of electronic cigarette devices (e-cigs) to deliver nicotine is key their potential replace combustible cigarettes. We compared delivery and subjective effects associated with the use two classes e-cigarettes
To identify factors associated with successful quitting at a free tobacco treatment clinic.A cohort study of the first 1021 patients who made quit attempt. Baseline and variables were recorded, logistic regression was used to abstinence 4-week 6-month follow-up.Three hundred twenty (31.3%) reported 6 months. Several markers low socioeconomic status high nicotine dependence predictive poorer smoking cessation outcomes. Compliance evidence-based improved outcome, as older age having more than...
Purpose Limited data are available on the survival of patients with breast cancer preexisting mental illness, and elderly women special interest because they experience highest incidence cancer. Therefore, we compared all-cause cancer-specific mortality for without illness. Methods A retrospective cohort study was conducted by using SEER-Medicare data, including 19,028 ≥ 68 years age who were diagnosed stage I to IIIa in United States from 2005 2007. Patients classified as having severe...
The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful products will need to have excellent side-effect profiles addition proven efficacy. New faster delivery nicotine replacement the promise addressing broader list indications, withdrawal during temporary abstinence...
Journal Article Randomized Controlled Trial of a Healthy Lifestyle Intervention Among Smokers With Psychotic Disorders Get access Amanda L. Baker, Baker Search for other works by this author on: Oxford Academic PubMed Google Scholar Robyn Richmond, Richmond Frances J. Kay-Lambkin, Kay-Lambkin Sacha Filia, Filia David Castle, Castle Jill M. Williams, Williams Terry Lewin, Lewin Vanessa Clark, Clark Robin Callister, Callister Natasha Weaver Nicotine & Tobacco Research, Volume 17, Issue 8,...
People with mental health problems have high rates of smoking, and represent a large proportion adult smokers in the United States. However, few public programs tobacco control address health. This study sought to determine if smoking is declining at comparable people different levels psychological distress. Time series analysis prevalence between 1997 2014 was undertaken, by level distress, age group, sex using data from US National Health Interview Survey, cross-sectional surveys....
The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful products will need to have excellent side-effect profiles addition proven efficacy. New faster delivery nicotine replacement the promise addressing broader list indications, withdrawal during temporary abstinence...